Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults
Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..
Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)
Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..